Introduction
RA, autoimmune diseases, tumor necrosis, TNF-α
AUTOIMMUNE DISEASES, TUMOR NECROSIS
Continuous therapeutic treatment is important in the context of chronic autoimmune diseases. Treatment persistence, or the total time from initiation to discontinuation of therapy, depends upon drug efficacy, patient satisfaction, safety, and tolerability and is therefore regarded as a useful measure of overall drug effectiveness [Golimumab is a human monoclonal antibody directed against tumor necrosis factor–α (TNF-α), a potent pro-inflammatory cytokine whose signaling contributes to autoimmune diseases [While golimumab retention was described previously in the pivotal Phase III clinical trials (RA: GO-BEFORE [